Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-11-21
2010-06-01
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
07728036
ABSTRACT:
The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.
REFERENCES:
patent: 2456443 (1948-12-01), Mueller et al.
patent: 3934034 (1976-01-01), Manning
patent: 4708964 (1987-11-01), Allen
patent: 4745160 (1988-05-01), Churchill
patent: 4774229 (1988-09-01), Jordan
patent: 4880637 (1989-11-01), Jordan
patent: 5008294 (1991-04-01), Neiss et al.
patent: 5663209 (1997-09-01), Huang
patent: 5827898 (1998-10-01), Khandwala
patent: 6039955 (2000-03-01), Sinnott
patent: 6214874 (2001-04-01), Huang et al.
patent: 6291524 (2001-09-01), Huang
patent: 6365787 (2002-04-01), Huang
patent: 6417234 (2002-07-01), Huang et al.
patent: 6545019 (2003-04-01), Posmantur
patent: 6608108 (2003-08-01), Huang
patent: 6750247 (2004-06-01), Crews et al.
patent: 6777444 (2004-08-01), Huang
patent: 6949558 (2005-09-01), Altieri et al.
patent: 6958411 (2005-10-01), Huang
patent: 2003/0215409 (2003-11-01), Quinn et al.
patent: 2004/0014721 (2004-01-01), Hensley
patent: 2004/0028758 (2004-02-01), Park et al.
patent: 2004/0127562 (2004-07-01), Huang
patent: 2005/0267208 (2005-12-01), Huang
patent: WO 88/03800 (1988-06-01), None
patent: WO 96/40090 (1996-12-01), None
Lambert et al. Tetra-O-methylnordihydroguaiaretic acid inhibits melanoma in vivo. Cancer Letters (Shannon, Ireland) (2001), 171(1), 47-56.
John Noel Gnabre, “Isolation of anti-HIV-1 lignans fromLarrea tridentateby counter-current chromatography,”Journal of Chromatography A, 719:353-364 (1996).
Jih Ru Hwu, “Antiviral Activities of Methylated Nordihydroguaiaretic Acids. 1. Synthesis, Structure Identification, and Inhibition of Tat-Regulated HIV Transactivation,”J. Med. Chem., 41:2994-3000 (1998).
Clark W. Perry, “Synthesis of Lignans. I. Nordihydroguaiaretic Acid,”J. Org. Chem, 37(26):4371-4376 (1972.
G. E. Amidon, “Citric Acid Monohydrate,” pp. 140-142.
K. Fowler, “Diethanolamine,” pp. 180-181.
P.J. Weller, “Hydrochloric Acid,” pp. 238-239.
M. G. Lee, “Lactic Acid,”pp. 272-273.
C. G. Cable, “Malic Acid,” pp. 311-312.
S. R. Goskonda, “Monoethanolamine,” pp. 350-351.
P.J. Weller, “Potassium Citrate,” pp. 429-430.
C. G. Cable, “Sodium Bicarbonate,” pp. 474-477.
G. E. Amidon, “Sodium Citrate Dihydrate,” pp. 482-484.
A. S. Kearney, “Sodium Phosphate, Dibasic,” pp. 493-495.
V. Conway, “Sodium Phosphate, Monobasic,” pp. 496-497.
K. D. Vaughan, “Tartaric Acid,” pp. 558-559.
S. R. Goskonda, “Triethanolamine,” pp. 572-573.
“Ionic Solutions and Electrolyte Equilibria,” Chapter 17, pp. 231-249.
Cathy Y. Poon, “Tonicity, Osmoticity, Osmolality, and Osmolarity,” Chapter 18, pp. 250-259.
William P. Armstrong, “Clinical Modulation of Oral Leukoplakia and Protease Activity by Bowman-Birk Inhibitor Concentrate in a Phase IIa Chemoprevention Trial,”Clinical Cancer Research, 6:4684-4691 (Dec. 2000).
K. Avgoustakis, “PLGA-mPEG nanparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties,”Journal of Controlled Release, 79:123-135 (2002).
A. Beletsi, “Effect of preparative variables on the properties of poly(dl-lactide-coglycolide)-methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery,” 182:187-197 (1999).
A. Branchi, “Lowering effects of four different statins on serum triglyceride level,”Eur. J. Clin. Pharmacol., 55:499-502 (1999).
H. Brem, “Biodegradable polymer implants to treat brain tumors,”Journal of Controlled Release, 74:63-67 (2001).
Won Seon Choi, “Inhalation delivery of proteins from ethanol suspensions,”PNAS, 98(20):11103-11107 (Sep. 25, 2001).
Timothy F. Cloughesy, “Intra-arterial carboplatin chemotherapy for brain tumors: A dose escalation study based on cerebral blood flow,”Journal of Neuro-Oncology, 35:121-131 (1997).
Fernanda G. De Felice, “Inhibition of Alzheimer's disease β-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy,”The FASEB Journal, 15:1297-1299 (May 2001).
Darius C. Desai M.D., “Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors,”Regulatory Peptides, 96:113-117 (2001).
Nancy D. Doolittle, “Safety and Efficacy of a Multicenter Study Using Intraarterial Chemotherapy in Conjunction with Osmotic Opening of the Blood-Brain Barrier for the Treatment of Patients with Malignant Brain Tumors,”Cancer, 88(3):637-647 (Feb. 1, 2000).
James G. Drougas, “Hepatic Artery Chemoembolization for Management of Patients with Advanced Metastatic Carcinoid Tumors,”The American Journal of Surgery, 175:408-412 (May 1998).
J. B. Epstein, “Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy,”Oral Oncology, 37:632-637 (2001).
Joel B. Epstein, “Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients,”Oral Surgery Oral Medicine Oral Pathology, 93(6):671-675 (Jun. 2002).
H. Fessi, “Nanocapsule formation by interfacial polymer deposition following solvent displacement,”International Journal of Pharmaceutics, 55:R1-R4 (1989).
Alison B. Fleming, “Pharmacokinetics of the Carmustine Implant,”Clin Pharmacokinet, 41(6):403-419 (2002.
L. Frölich, “Free Radical Mechanisms in Dementia of Alzheimer Type and the Potential for Antioxidative Treatment,”Arzneim.-Forsch./Drug Res., 45(1), Nr. 3a, pp. 443-446(1995).
Jie Fu, “New polymeric carriers for controlled drug delivery following inhalation or injection,”Biomaterials, 23:4425-4433 (2002).
I. Gonda, “Inhalation delivery systems with compliance and disease management capabilities,”Journal of Controlled Release, 53:269-274 (1998).
Maya S. Gowri, “Masoprocol Lowers Blood Pressure in Rats With Fructose-Induced Hypertension,”American Journal of Hypertension, 12:744-746 (1999).
Jonathan D. Heller, “Tetra-O-methyl Nordihydroguaiaretic Acid Induces G2Arrest in Mammalian Cells and Exhibits Tumoricidal Activity in Vivo,”Cancer Research, 61:5499-5504 (Jul. 15, 2001).
Carol Hermann, “Diagnostic and Pharmacological Approaches in Alzheimer's Disease,”Drugs&Aging, 1(2):144-162 (1991).
David R. Howlett, “Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans,”Biochem. J., 340:283-289 (1999) (Printed in Great Britain).
Anders G. Olsson, M.D., “A 52-Week, Multicenter, Randomized, Parallel-Group, Double-Blind, Double-dummy Study to Assess the Efficacy of Atorvastatin and Simvastatin in Reaching Low Density Lipoprotein Cholesterol and Triglyceride Targets: The Treat-to Target (3T) Study,”Clinical Therapeutics, pp. 119-138 (Copyright © 2003 Excerpta Medica, Inc.).
Manfred Wilhelm, “Poly(styrene-ethylene oxide) Block Copolymer Micelle formation in Water: A Fluorescence Probe Study,”Macromolecules, 24:1033-1040 (1991).
Huaihung Danny Kao, “Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water Soiluble Prodrugs,”Pharmaceutical Research, 17(8):978-984 (2000).
Eun Hee Kim, “Roscovitine sensitizes gl
Chang Chih-Chuan
Frazer Neil
Heller Jonathan
Huang Ru Chih C.
Liang Yu-Chuan
Erimos Pharmaceuticals, LLC
Johns Hopkins University
Keller Michael J.
McDermott, Will and Emery
Weddington Kevin
LandOfFree
Methods for delivery of catecholic butanes for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for delivery of catecholic butanes for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for delivery of catecholic butanes for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200299